Association of depth of target lesion response to brigatinib with outcomes in patients with ALK inhibitor-naive ALK plus NSCLC in ALTA-1L
Camidge, D. R. Kim, H. R. Ahn, M. J. Yang, J. C. Han, J. Y. Hochmair, M. Lee, K. H. Delmonte, A. Campelo, R. G. Kim, D. W.
Camidge, D. R.
Kim, H. R.
Ahn, M. J.
Yang, J. C.
Han, J. Y.
Hochmair, M.
Lee, K. H.
Delmonte, A.
Campelo, R. G.
Kim, D. W.
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Hochmair M, et al. Association of depth of target lesion response to brigatinib with outcomes in patients with ALK inhibitor-naive ALK plus NSCLC in ALTA-1L. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680302258.